Farallon Capital Management has established a significant new position in BridgeBio Pharma (BBIO), a biopharmaceutical company focused on genetic conditions. According to its latest 13F filing, the investment firm acquired 9.37 million shares, valued at approximately $695.48 million. This new holding represents a substantial 3.96% of Farallon's reported portfolio.
This disclosure was made in a quarterly report filed with the SEC on August 14, 2026, which reflects holdings as of March 31, 2026. Such filings reveal positions taken in the preceding quarter, not same-day trades. During the first quarter of 2026, BridgeBio reported total revenues of $194.5 million and ended the period with $940.2 million in cash, cash equivalents, and marketable securities.